SCHEMBL13166707

SCHEMBL13166707

O=C(Nc1ccc(N2CCCC2)c(Cl)c1)C(c1ccccc1)c1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY2R P49146 4/20 0.77
KDM4E B2RXH2 2/20 0.70
RECQL P46063 1/20 0.70
MAPT P10636 10/20 0.67
KMT2A Q03164 6/20 0.67
NPSR1 Q6W5P4 3/20 0.67
USP2 O75604 2/20 0.67
ESR1 P03372 1/20 0.67
NR4A1 P22736 1/20 0.67
PTK2B Q14289 1/20 0.67
ALDH1A1 P00352 10/20 0.64
MEN1 O00255 5/20 0.64
ALOX12 P18054 1/20 0.64
RAB9A P51151 6/20 0.56
NPC1 O15118 6/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
LMNA P02545 3/20 0.56
NFKB1 P19838 2/20 0.56
NFKB2 Q00653 2/20 0.56
RELA Q04206 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29967304 0.85 NPY2R (0.74) NPY2RKDM4ERECQLMAPTKMT2A
SCHEMBL13856567 0.81 MAPT (1.00) KDM4EMAPTKMT2ANPSR1USP2
SCHEMBL13949529 0.76 MEN1 (0.66) NPY2RMAPTKMT2AALDH1A1MEN1
SCHEMBL1594391 0.75 KMT2A (0.66) NPY2RKDM4EMAPTKMT2ANPSR1
SCHEMBL7651873 0.75 KMT2A (0.69) KDM4ERECQLMAPTKMT2ANPSR1
SCHEMBL1593432 0.74 KMT2A (0.64) NPY2RKDM4EMAPTKMT2ANPSR1
SCHEMBL6566906 0.74 POLB (0.66) NPY2RKDM4EMAPTKMT2ANPSR1
SCHEMBL7655884 0.74 KMT2A (0.71) KDM4ERECQLMAPTKMT2ANPSR1
SCHEMBL7649651 0.72 ALDH1A1 (0.65) KDM4ERECQLMAPTKMT2ANPSR1
SCHEMBL6454551 0.72 KDM4E (0.66) NPY2RKDM4ERECQLMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100248365-A1 GANGLIOSIDE BIOSYNTHESIS MODULATORS ZACHARON PHARMACEUTICALS, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100248365-A1 GANGLIOSIDE BIOSYNTHESIS MODULATORS UGCG, MAGT1, STT3B NPY2R 2970/4885KDM4E 2180/4885RECQL 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.